Should You Buy Nike Stock Before Oct. 1?
Source: Nasdaq

Nike will report fiscal Q1 2027 earnings on Oct. 1 after its shares fell nearly 80% from their 2021 peak to a 12-year low and the company was removed from the S&P 100. Fiscal 2026 revenue was essentially flat at $46.4B while profit fell 3% to $3.1B, and analysts expect revenue to decline another 3% in Q1 and 2% for fiscal 2027. Despite a 17x P/E and 4.6% dividend yield, fiscal 2026 dividends of $2.4B exceeded $2.2B of free cash flow, creating potential financial strain if growth does not recover.
Analysis
The relevant setup into Oct. 1 is not valuation but the credibility of the reset: NKE must show that wholesale re-engagement, product launches and inventory discipline can coexist without sacrificing gross margin. A revenue miss alone is likely manageable given depressed expectations; the more damaging outcome is another cut to FY27 margin or cash-flow expectations, which would expose the dividend as a capital-allocation constraint rather than a valuation support. Index-related forced selling should now be largely complete, but its removal reduces passive ownership and can leave the shares more vulnerable to an earnings-gap move.
ONON and adidas (ADS) retain a favorable competitive position if Nike needs heavier promotional activity to regain distribution and consumer attention. The second-order risk is category-wide: sustained Nike discounting would pressure footwear sell-through and wholesale margins at ONON, DECK and SKX, even if their unit growth remains superior. Conversely, evidence that Nike is restoring full-price sell-through would be a more important signal than a modest sales beat, as it reduces the probability of a prolonged industry promotional cycle over the next 6-18 months.
Consensus bearishness may be underestimating the asymmetry if management can stabilize North America and guide to sequential improvement: a low-teens earnings multiple and elevated income-oriented ownership can support a sharp 10-15% relief rally. But that is a trading outcome, not yet a durable long thesis; recovery requires multiple product cycles and retailer reorder data, likely over 2-4 quarters. Falsify the bearish view with positive constant-currency wholesale orders, stable gross margin despite investment, and free cash flow covering dividends; reinforce it if FY27 EBIT/FCF guidance resets lower or inventory rises faster than sales.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.58
Ticker Sentiment
Key Decisions for Investors
- Remain underweight NKE into Oct. 1; do not add long exposure solely on yield or P/E. Reassess only if guidance implies sequential revenue improvement and dividend coverage through free cash flow, with a 1-3 month relief-rally target rather than a structural allocation.
- Use a tactical long ONON / short NKE pair over the next 1-3 months, sized modestly: ONON retains relative brand momentum while NKE bears execution and margin-reset risk. Exit if NKE reports improving full-price sell-through and wholesale order momentum; principal risk is a heavily shorted NKE earnings squeeze.
- For existing NKE holders needing event protection, buy near-dated downside puts or implement a put spread through the earnings date; the key downside catalyst is a FY27 EBIT or cash-flow guide-down, which could reopen dividend-sustainability concerns.
- Monitor DECK and SKX after Nike results as read-through shorts only if management signals broad-based discounting or elevated channel inventory. Without confirmation of promotional intensity, avoid forcing a sector short because company-specific Nike execution remains the primary driver.
More News
- The Pentagon Is Buying eVTOLs. Here's Which Stock Wins the Defense Money.
- Nvidia Is Weighing a $10 Billion Stake in Anthropic's IPO. It Would Be Buying Its Own Demand.
- Can Cloudflare CEO Matthew Prince save the web from AI?
- Bank of America says Nvidia and these other stocks are on sale
- Major Milestone Passed In Iridium/Rocket Lab Tie Up
- 2 Healthcare Stocks That Just Delivered Great News for Investors